Patent ID: 6444221
Filing Date: 2002-09-03
Classification: A61K,Y02A

Abstract:
A method of treating a mammalian subject for the symptoms of a chronic inflammatory disorder, said method comprising daily systemic administration entirely by the oral route to said subject a composition consisting essentially of(a) from about 15 mg/kg to about 450 mg/kg of a water soluble primary amine compound having a molecular weight in the range of 100 to about 1,400 of the formula wherein the 6-membered ring is phenyl, cyclohexadiene, cyclohexene or cyclohexane; and whereinR1 is â€”NH2; aminoalkyl- having 1-10 carbons; â€”NHC(&boxH;NH)NH2; â€”(CH2)nNHC(&boxH;NH)NH2 wherein n is 1-10; â€”C(&boxH;NH)NH2; â€”(CH2)nâ€”CH&boxH;NC(&boxH;NH)NH2 wherein n is 1-10; â€”NHC(&boxH;NH)NHNH2; â€”(CH2)nNHC(&boxH;NH)NHNH2 wherein n is 1-10; â€”(CH2)nâ€”CH&boxH;NC(&boxH;NH)NHNH2 wherein n is 1-10; â€”NHNHC(&boxH;NH)NH2; â€”(CH2)nâ€”NHNHC(&boxH;NH)NH2 wherein n is 1-10; or â€”(CH2)nâ€”CH&boxH;Nâ€”NHC(&boxH;NH)NH2 wherein n is 1-10; R2 is H; â€”OH; â€”Oâ€”CH3; â€”Oâ€”R wherein R is alkyl of 2-10 carbons; aminoalkyl wherein the alkyl group is 1-10 carbons; â€”SO3H; â€”CH3; and â€”(CH2)nCH3 wherein n is 1-10; Râ€² and Râ€³ are â€”H, OH or CH3; and m is 0 or 1; and the pharmaceutically acceptable salts, esters, and amide derivatives thereof; and (b) a therapeutically effective amount of at least one co-agent selected from the group consisting of an anti-oxidant and free radical trapping compound with the proviso that dimethyl sulfoxide is exempted from this group, a compound having indirect anti-oxidant activity, a vitamin, a compound having conjugating activity which facilitates kidney drug elimination, a metabolite at risk of depletion, a sulfhydryl compound and a compound which facilitates glutathione activity; wherein the amount of the primary agent on a molar basis is always greater than that of a co-agent.